Harmony Biosciences Holdings, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jeffrey Dayno
- Full Time Employees
- 293
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 630 West Germantown Pike Plymouth Meeting PA United States of America 19462
- IPO Date
- Aug 19, 2020
- CIK
- 0001802665
- Website
- harmonybiosciences.com
- Similar Companies
- Business
- Harmony Biosciences Holdings, Inc. develops and commercializes therapies for rare neurological disorders, primarily focusing on innovative treatments to address unmet medical needs. Its core product portfolio centers on WAKIX (pitolisant), the first and only FDA-approved oral medication for excessive daytime sleepiness in adult patients with narcolepsy. The company also develops pipeline candidates such as EPX-100 (clemizole hydrochloride) for Dravet syndrome, EPX-200 (lorcaserin) targeting other rare neurological conditions, and CBS-104, a regenerative cellular therapy for refractory epilepsy. Harmony Biosciences markets these products primarily in the United States and pursues expansion through clinical development in other rare disease indications. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, the company strategically expanded by acquiring Epygenix Therapeutics in 2024, gaining late-stage epilepsy assets and enhancing its CNS rare disease pipeline. Recently, it announced positive results from a pivotal bioequivalence study for pitolisant’s gastro-resistant formulation, setting the stage for a New Drug Application submission in early 2026, and is advancing phase 3 clinical trials for EPX-100 in Dravet syndrome with topline data expected in 2026. Additionally, Harmony entered into a strategic financing agreement with Blackstone in 2024, securing up to $330 million to support its growth initiatives. The company actively presents clinical data at major scientific forums and continues developing multiple CNS programs targeting rare neurological disorders across the U.S. and beyond.
Company News
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
Canada Pension Plan Investment Board Takes $1.21 Million Position in Harmony Biosciences Holdings, Inc. $HRMY
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
Aurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMY
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline
Harmony Biosciences Holdings, Inc. $HRMY Position Raised by California State Teachers Retirement System
4 Healthcare Stocks to Watch as Defensive Demand Strengthens
4 Stocks Trading Near 52-Week High With More Upside Potential
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
Harmony Biosciences Q2 Earnings Call Highlights
Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated
HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up
Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2026 Earnings Call Transcript
Harmony Biosciences Q2 Earnings Call Highlights
Harmony Biosciences Holdings, Inc. (HRMY) Beats Q2 Earnings and Revenue Estimates
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
4 Value Stocks to Buy as Fed Holds Rates, Mideast Risks Rise
HRMY or ACAD: Which Is the Better Value Stock Right Now?